| Implantable gastric stimulator does not prevent the increase in plasma ghrelin levels that occurs with weight loss. | |
| | |
MedLine Citation:
|
PMID: 21681227 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The SHAPE (Screened Health Assessment and Pacer Evaluation) trial was a 24 month randomized multicenter placebo-controlled study to determine the efficacy of an implantable gastric stimulator (IGS) for weight loss. This report is an investigator-initiated sub-study at one site designed to assess whether IGS affects plasma levels of ghrelin and peptide YY (PYY). The device was implanted in all subjects but was activated in the Treatment group (n = 7, BMI = 41.5 ± 2.0 kg/m2) and remained inactive in the Control (n = 6, BMI = 39.5 ± 1.7 kg/m2) during the first 12 months. IGS was activated in both groups during months 12-24. Fasting venous blood was drawn at months 0, 12, and 24 and an oral glucose tolerance test (OGTT) was performed at month 12. Although there was no difference in weight loss at 6 months (Control: -6.6 ± 1.5% vs. Treatment: -6.2 ± 1.4%), at 24 months the Control group exhibited weight gain from baseline (+2.2 ± 1.5%) that was significantly different from the weight loss in the Treatment group (-1.9 ± 1.4%; P < 0.05). At 12 months, fasting ghrelin was significantly increased (P < 0.05) in the Treatment group (285 ± 35 to 336 ± 35 pg/ml; weight change, -4.9 ± 1.4%), but not in the Control (211 ± 36 to 208 ± 35 pg/ml; weight change, -3.4 ± 1.5%). No significant change was observed in postprandial suppression of plasma ghrelin or in fasting and postprandial PYY levels. In conclusion, IGS does not prevent the increase in fasting plasma ghrelin levels associated with weight loss. Further studies are needed to determine whether changes in technology can improve weight loss and maintenance, perhaps using gut hormones as biomarkers of possible efficacy. |
| | |
Authors:
|
Judith Korner; Anindita Nandi; Suzanne M Wright; Jonathan Waitman; Donald J McMahon; Marc Bessler; Louis J Aronne |
Related Documents
:
|
8743517 - Renal effects of prolonged antihypertensive treatment with diltiazem. 7273267 - Renal clearance of methotrexate in man during high-dose oral and intravenous infusion t... 3780837 - A comparison of the pharmacokinetics and diuretic effects of two loop diuretics, torase... 6423877 - Experimental observations on peritoneal transport in rabbits. 1484917 - Neuroendocrine aspects of primary endogenous depression: xii. receiver operating charac... 18546007 - The clinical role of vascular endothelial growth factor (vegf) system in the pathogenes... |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: Obesity (Silver Spring, Md.) Volume: 19 ISSN: 1930-739X ISO Abbreviation: Obesity (Silver Spring) Publication Date: 2011 Oct |
Date Detail:
|
Created Date: 2011-10-28 Completed Date: 2012-03-27 Revised Date: 2012-08-13 |
Medline Journal Info:
|
Nlm Unique ID: 101264860 Medline TA: Obesity (Silver Spring) Country: United States |
Other Details:
|
Languages: eng Pagination: 1935-9 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Columbia University College of Physicians & Surgeons, New York, New York, USA. jk181@columbia.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Double-Blind Method Electric Stimulation* Electrodes, Implanted Fasting Female Ghrelin / blood* Glucose Tolerance Test Humans Male Middle Aged Obesity, Morbid / blood, therapy* Peptide YY / blood Postprandial Period Weight Gain Weight Loss / physiology* Young Adult |
| Grant Support | |
ID/Acronym/Agency:
|
R01DK 072011/DK/NIDDK NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Ghrelin; 106388-42-5/Peptide YY |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: High-volume exercise program in obese bariatric surgery patients: a randomized, controlled trial.
Next Document: Birth weight and subsequent adiposity gain in Swedish children and adolescents: a 6-year follow-up s...